The California health system has expanded its partnership with CancerIQ to integrate risk assessment and oncology patient management into its EHR.
The mCODE team recently released standards for inputting genomic and other data into patient records to boost patient record transferability and trial participation.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
The California-based health system is expanding its partnership with clinical decision support vendor CancerIQ to integrate risk assessment into the Cerner EHR workflow.
Standards for interoperability and better cooperation among stakeholders will help unleash the power of genomics in cancer care, says the head of the Biden Cancer Initiative.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
The test is designed to determine breast cancer risk by analyzing a number of factors including breast density, breast biopsy history, and a polygenic score.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
The year-old Princess Máxima Center, based in Utrecht, has turned to bioinformatics firm The Hyve to address integration and interoperability issues.
Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.
OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.
Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.
Sophia's STS molecular diagnostic application runs on top of the Sophia AI platform to detect and characterize genomic alterations in solid tumors.
In the JAMA study, researchers confirmed the previously known clinical and genomic features of NSCLC patients in their large clinico-genomics database.
Studies presented at the AACR meeting demonstrated how the registry can be used to evaluate how cancer patients with rare tumor markers respond to treatments.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
The St. Louis-based firm will offer a sequencing service to help researchers separate target signals from errors made during next-generation sequencing.